Experimental animal study of docetaxel combined with carboplatin in the treatment of retinoblastoma

Song,Caiping; Zhang,Qiang

doi:10.3892/ol.2018.8623

Experimental animal study of docetaxel combined with carboplatin in the treatment of retinoblastoma

Authors:
- Caiping Song
- Qiang Zhang
View Affiliations

Affiliations: Department of Ophthalmology, Weihai Municipal Hospital, Weihai, Shandong 264200, P.R. China, Department of Ophthalmology, Yantai Hospital of Traditional Chinese Medicine, Yantai, Shandong 264000, P.R. China
Published online on: May 3, 2018 https://doi.org/10.3892/ol.2018.8623
Pages: 235-238
Copyright: © Song et al. This is an open access article distributed under the terms of Creative Commons Attribution License.

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

The synergistic effects of docetaxel (DTX) combined with carboplatin in the treatment of retinoblastoma (RB) was explored in mouse RB xenografts compared with carboplatin alone and DTX alone groups. Retinoblastoma Y-79 cells (4.0x107/ml) were injected into the vitreous body of the right eye of mice to establish the mouse model of RB xenografts. Then the mice were randomly divided into 4 groups (n=30): DTX combined with carboplatin group (group A), carboplatin group (group B), DTX group (group C) and blank control group (group D). The changes in tumors, the survival time of mice, and the synergistic effects of DTX combined with carboplatin were observed and analyzed. The diameters and weight of the right eyeballs of the Institute for Cancer Research (ICR) mice were significantly larger and higher than those of the left eyeballs in each group, respectively (p<0.05). The diameters and weight in group A were significantly shorter and lighter than those in the other three groups, respectively (p<0.05), and there was no significant difference compared with that of normal eyeballs (p>0.05). There was no difference in diameter and weight between group B and group C (p>0.05), but the diameters and weight were shorter and lighter than those in group D, respectively (p<0.05). The survival time of ICR mice in groups A, B and C was significantly longer than that in group D (p<0.05). The survival time in group A was significantly longer than that in groups B and C (p<0.05). There was no significant difference in the survival time between the group B and group C (p>0.05). DTX, carboplatin and the combination of the two have significant inhibitory effects on RB; however, DTX combined with carboplatin has a better therapeutic effect on RB.

View Figures

View References

1	Villanueva: Tumorigenesis: Establishing the origin of retinoblastoma. Nat Rev Cancer. 14:706–707. 2014.
2	Thériault BL, Dimaras H, Gallie BL and Corson TW: The genomic landscape of retinoblastoma: A review. Clin Exp Ophthalmol. 42:33–52. 2014. View Article : Google Scholar : PubMed/NCBI
3	Kamihara J, Bourdeaut F, Foulkes WD, Molenaar JJ, Mossé YP, Nakagawara A, Parareda A, Scollon SR, Schneider KW, Skalet AH, et al: Retinoblastoma and neuroblastoma predisposition and surveillance. Clin Cancer Res. 23:e98–e106. 2017. View Article : Google Scholar : PubMed/NCBI
4	Sethi RV, Shih HA, Yeap BY, Mouw KW, Petersen R, Kim DY, Munzenrider JE, Grabowski E, Rodriguez-Galindo C, Yock TI, et al: Second nonocular tumors among survivors of retinoblastoma treated with contemporary photon and proton radiotherapy. Cancer. 120:126–133. 2014. View Article : Google Scholar : PubMed/NCBI
5	Borghaei H, Paz-Ares L, Horn L, Spigel DR, Steins M, Ready NE, Chow LQ, Vokes EE, Felip E, Holgado E, et al: Nivolumab versus docetaxel in advanced nonsquamous non-small-cell lung cancer. N Engl J Med. 373:1627–1639. 2015. View Article : Google Scholar : PubMed/NCBI
6	Sikov WM, Berry DA, Perou CM, Singh B, Cirrincione CT, Tolaney SM, Kuzma CS, Pluard TJ, Somlo G, Port ER, et al: Impact of the addition of carboplatin and/or bevacizumab to neoadjuvant once-per-week paclitaxel followed by dose-dense doxorubicin and cyclophosphamide on pathologic complete response rates in stage II to III triple-negative breast cancer: CALGB 40603 (Alliance). J Clin Oncol. 33:13–21. 2015. View Article : Google Scholar : PubMed/NCBI
7	Corson TW, Samuels BC, Wenzel AA, Geary AJ, Riley AA, McCarthy BP, Hanenberg H, Bailey BJ, Rogers PI, Pollok KE, et al: Multimodality imaging methods for assessing retinoblastoma orthotopic xenograft growth and development. PLoS One. 9:e990362014. View Article : Google Scholar : PubMed/NCBI
8	Wong JR, Morton LM, Tucker MA, Abramson DH, Seddon JM, Sampson JN and Kleinerman RA: Risk of subsequent malignant neoplasms in long-term hereditary retinoblastoma survivors after chemotherapy and radiotherapy. J Clin Oncol. 32:3284–3290. 2014. View Article : Google Scholar : PubMed/NCBI
9	Kleinerman RA, Yu CL, Little MP, Li Y, Abramson D, Seddon J and Tucker MA: Variation of second cancer risk by family history of retinoblastoma among long-term survivors. J Clin Oncol. 30:950–957. 2012. View Article : Google Scholar : PubMed/NCBI
10	Kleinerman RA, Schonfeld SJ and Tucker MA: Sarcomas in hereditary retinoblastoma. Clin Sarcoma Res. 2:152012. View Article : Google Scholar : PubMed/NCBI
11	Singh SK, Banerjee S, Acosta EP, Lillard JW and Singh R: Resveratrol induces cell cycle arrest and apoptosis with docetaxel in prostate cancer cells via a p53/p21WAF1/CIP1 and p27KIP1 pathway. Oncotarget. 8:17216–17228. 2017. View Article : Google Scholar : PubMed/NCBI
12	Kang KB, Francis JH and Abramson DH: What do we know about intraocular carboplatin? J Ocul Pharmacol Ther. 30:688–690. 2014. View Article : Google Scholar : PubMed/NCBI
13	Brahmer J, Reckamp KL, Baas P, Crinò L, Eberhardt WE, Poddubskaya E, Antonia S, Pluzanski A, Vokes EE, Holgado E, et al: Nivolumab versus docetaxel in advanced squamous-cell non-small-cell lung cancer. N Engl J Med. 373:123–135. 2015. View Article : Google Scholar : PubMed/NCBI
14	Swain SM, Kim SB, Cortés J, Ro J, Semiglazov V, Campone M, Ciruelos E, Ferrero JM, Schneeweiss A, Knott A, et al: Pertuzumab, trastuzumab, and docetaxel for HER2-positive metastatic breast cancer (CLEOPATRA study): Overall survival results from a randomised, double-blind, placebo-controlled, phase 3 study. Lancet Oncol. 14:461–471. 2013. View Article : Google Scholar : PubMed/NCBI
15	Kwon ED, Drake CG, Scher HI, Fizazi K, Bossi A, van den Eertwegh AJ, Krainer M, Houede N, Santos R, Mahammedi H, et al: CA184-043 Investigators: Ipilimumab versus placebo after radiotherapy in patients with metastatic castration-resistant prostate cancer that had progressed after docetaxel chemotherapy (CA184-043): A multicentre, randomised, double-blind, phase 3 trial. Lancet Oncol. 15:700–712. 2014. View Article : Google Scholar : PubMed/NCBI
16	Langer CJ, Gadgeel SM, Borghaei H, Papadimitrakopoulou VA, Patnaik A, Powell SF, Gentzler RD, Martins RG, Stevenson JP, Jalal SI, et al: KEYNOTE-021 investigators: Carboplatin and pemetrexed with or without pembrolizumab for advanced, non-squamous non-small-cell lung cancer: A randomised, phase 2 cohort of the open-label KEYNOTE-021 study. Lancet Oncol. 17:1497–1508. 2016. View Article : Google Scholar : PubMed/NCBI
17	O'Shaughnessy J, Schwartzberg L, Danso MA, Miller KD, Rugo HS, Neubauer M, Robert N, Hellerstedt B, Saleh M, Richards P, et al: Phase III study of iniparib plus gemcitabine and carboplatin versus gemcitabine and carboplatin in patients with metastatic triple-negative breast cancer. J Clin Oncol. 32:3840–3847. 2014. View Article : Google Scholar : PubMed/NCBI
18	Katsumata N, Yasuda M, Isonishi S, Takahashi F, Michimae H, Kimura E, Aoki D, Jobo T, Kodama S, Terauchi F, et al: Japanese Gynecologic Oncology Group: Long-term results of dose-dense paclitaxel and carboplatin versus conventional paclitaxel and carboplatin for treatment of advanced epithelial ovarian, fallopian tube, or primary peritoneal cancer (JGOG 3016): A randomised, controlled, open-label trial. Lancet Oncol. 14:1020–1026. 2013. View Article : Google Scholar : PubMed/NCBI
19	Li A, Wei ZJ, Ding H, Tang HS, Zhou HX, Yao X and Feng SQ: Docetaxel versus docetaxel plus cisplatin for non-small-cell lung cancer: A meta-analysis of randomized clinical trials. Oncotarget. 8:57365–57378. 2017.PubMed/NCBI
20	Bouman-Wammes EW, de Munck L, van den Berg HP, Beeker A, Smorenburg CH, Verheul HMW, Gerritsen WR and van den Eertwegh AJM: A randomized phase II trial of docetaxel plus carboplatin versus docetaxel in patients with castration-resistant prostate cancer who have progressed after response to prior docetaxel chemotherapy: The RECARDO trial. Eur J Cancer. 90:1–9. 2018. View Article : Google Scholar : PubMed/NCBI